drugset / Trial / NCT02985632

A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants

NCT02985632

Phase 1 Withdrawn Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

An oral dose of BMS-986141 administered in Hepatic Impairment and Healthy Participants to evaluate pharmacokinetics in this patient population.

Timeline

Start
2017-01-11
Primary completion
2017-05-18
Completion
2017-07-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986141 Small molecule Oral

Indications

No indication recorded.